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The current issue of the British Journal of Cancer contains a well-
conducted meta-analysis of six small randomised trials comparing
appropriate surgery, with or without tamoxifen to tamoxifen alone
as primary treatment for elderly women with operable breast
cancer. The meta-analysis included 517 women treated in studies
of surgery plus tamoxifen compared to tamoxifen alone, and 247
women treated in studies of surgery compared to tamoxifen alone.
A meta-analysis of each subgroup showed significant improvement
in progression-free survival (hazard ratio (HR)¼0.55; 95%
confidence interval (CI) 0.39–0.77; P¼0.006) for surgery in
comparison to adjuvant tamoxifen and 0.65 (95% CI 0.53–0.81;
P¼0.0001) for surgery plus tamoxifen in comparison to tamoxifen
alone. Overall survival was not improved in the meta-analysis of
surgery alone compared to tamoxifen alone, but was marginally
significantly better for adjuvant tamoxifen plus surgery compared
to adjuvant tamoxifen alone (HR¼0.86; 95% CI, 0.83–1; P¼0.06).
Interestingly, a previous meta-analysis by Mustacchi et al (1994)
also suggested a marginally improved risk ratio of 0.86 (P¼0.09)
for adjuvant tamoxifen and surgery in comparison to tamoxifen
alone for overall survival and 0.70 (Po0.05) for breast cancer-
related survival.
The paradigm that women aged 70 and over might receive
primary treatment for breast cancer with tamoxifen or other
endocrine therapy alone, based on the concept that they are less fit
for surgery because of age and co-morbidity, was developed in the
1980s and has been since then considered appropriate to a greater
or lesser degree in various countries. Particularly in the United
Kingdom, this approach, apparently, has been used in as many
as 42% of women in this age group regardless of whether
co-morbidity was present or not (Wyld et al, 2004).
This meta-analysis however, and that previously published by
Mustacchi, as well as a re-examination of the life expectancy of
women in their 70s today, would suggest that to approach these
women differently from their younger sisters may be quite
inappropriate.
In fact, the annual incidence of breast cancer increases with age,
and divided by decade, more women are diagnosed with breast
cancer in the combined decades of their 70s and 80s than in their
50s or their 60s. Unfortunately, most studies of breast cancer
therapy worldwide have, at least until recently, specifically
excluded women over 70 or even over 65, in itself a form of ageism.
In addition, physicians often tend to underestimate life
expectancy in elderly women. Although the life expectancy of
women born today in most countries of the developed world is well
over 70, women who have already reached their 70s are of course
likely to live to be even older. Today in Canada, the average life
expectancy for a woman of 70 without particular morbidity is more
than 16 years and that for a 75-year-old is almost 13 years (Ottawa,
2006). The median time to progression in women in the studies
included in this meta-analysis who received only endocrine
therapy is not available in this publication; however, Kenny et al
(1998) reported that whereas 70% of those receiving surgery alone
were free of local disease at 24 months, only 47% of those receiving
tamoxifen alone were free of local disease (Kenny et al, 1998).
Similarly, the GRETA trial showed that local progression at 36
months was 25% for primary tamoxifen and only 6% for surgery
plus tamoxifen. These numbers suggest that local control with
tamoxifen alone is quite inadequate for women with this life
expectancy.
The only available quality of life data suggests that in one study,
3 months after the start of treatment, the surgery group had more
psychosocial morbidity (P¼0.03), but that there was no difference
between the two groups at 2 years (Fallowfield et al, 1994).
Another factor that contributes to undertreatment in women in
this age group is that older women may be less likely to seek
information, or to be assertive about therapy choices. They may
also, on occasion, feel that they cannot undertake hospital
admission or protracted treatment such as daily radiation therapy
because of their responsibilities in caring for an elderly partner.
Today however, with the availability of effective conservative
surgery including breast conserving surgery, and sentinel node
dissection with nodal sampling, even elderly patients probably
require minimal hospitalisation if offered appropriate homecare
support following their surgery. As stated by Hind et al, both
mastectomy and wide local excision have, for several decades, had
low mortality rates (Hunt et al, 1980; Wyld and Reed, 2004).
Furthermore, modern anaesthesia methods should reduce surgical
risk even in those with accompanying co-morbidity. Although
breast surgery-related morbidity may impact on quality of life, if
only lumpectomy or lumpectomy and sentinel node dissection is
used, such morbidity could be minimised.
Complete axillary dissection should only be necessary in those
with involved nodes at sentinel node sampling. Axillary dissection
is generally considered to contribute to local control, to guide the
selection of systemic therapy, and perhaps to have some long-term
effect on survival, although with competing risks of death in this
patient population such an effect, if any, would be minor. If the
tumour is large enough and of high enough histologic risk to
require systemic therapy in any case, axillary dissection or
sampling might not be required except for reasons of local control.
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lumpectomy, radiation therapy is actually generally well tolerated
in the elderly. Daily visits may be required, but with a variety of
brachytherapy approaches being explored, even this may not be
necessary. Ongoing trials of chemotherapy in this age group
(Biganzoli et al, 2004; Muss et al, 2005) may also help us to see
whether adjuvant chemotherapy will provide more gains than
negative effects for these older women.
In conclusion, to approach women in their 70s without seriously
considering the potential positive benefit of appropriate surgery
including complete tumour resection and axillary sampling, and
consideration of radiation therapy, as well as adequate systemic
therapy, would seem inappropriate. Has this policy been perhaps a
method of rationing care? – or a thoughtless application of ageism?
In fact, what would be appropriate for the 50-year-old may be
equally appropriate for the 70-year-old.
So, it would seem that treatment decisions in women over 70
should be made more in relation to their general health than to their
age, and should be similar to those made in women in their 50s and
60s unless serious co-morbidities exist. More trials involving this
group of women should be designed and carried out in order to
have better data to use for decision-making in these women.
Although apparently up to 40% of women over 70 have been treated
with endocrine therapy alone in the UK, fewer than 1000 became
part of the randomised trials examining this approach. However,
these trials, although small, have been pivotal, in that their
combination in meta-analysis has allowed us to critically examine
and hopefully improve our approach to these patients.
With otherwise healthy women of 70 expected to live well into
their 80s and perhaps 90s, we must abandon ageist approaches in
the treatment of breast cancer as well as in other areas of medical
care. Remembery70 is the new 50!
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